Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HALOZYME THERAPEUTICS, INC.HALO · Entity 793 | SVP, CHIEF TECHNICAL OFFICER | February 25, 2025 | February 27, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HALOZYME THERAPEUTICS, INC.
Report date February 25, 2025 · Filed February 27, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 173,756 |
Ending reported balance
After 2025-02-27 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2025-02-25 · Sale · Disposed 9,300 · Balance 186,153 F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024. F2: Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.54 to $58.47. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 2 · 2025-02-25 · Sale · Disposed 700 · Balance 185,453 F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024. F3: Represents a weighted average sales price per share. These shares were sold at prices ranging from $58.54 to $58.91. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 3 · 2025-02-26 · Sale · Disposed 9,400 · Balance 176,053 F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024. F4: Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.62 to $58.61. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 4 · 2025-02-26 · Sale · Disposed 600 · Balance 175,453 F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024. F5: Represents a weighted average sales price per share. These shares were sold at prices ranging from $58.62 to $58.68. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 5 · 2025-02-27 · Sale · Disposed 1,597 · Balance 173,856 F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024. F6: Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.71 to $58.66. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 6 · 2025-02-27 · Sale · Disposed 100 · Balance 173,756 F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024.
F2: Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.54 to $58.47. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3: Represents a weighted average sales price per share. These shares were sold at prices ranging from $58.54 to $58.91. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F4: Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.62 to $58.61. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F5: Represents a weighted average sales price per share. These shares were sold at prices ranging from $58.62 to $58.68. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F6: Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.71 to $58.66. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 10, 2022 Filed Feb 15, 2022 00:29 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 8,133 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001201 · edgar.xml · nonDerivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,979 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 12, 2021 Filed Oct 12, 2021 23:06 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 8,050 | $0.00 Strike: $13.10 | $0.00 |
DisclosureSEC source: 0001179110-21-009380 · edgar.xml · derivative · entry 2 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,050 shares Expires 2024-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option was granted on February 6, 2014 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter. Read SEC document |
| October 12, 2021 Filed Oct 12, 2021 23:06 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 8,050 | $13.10 | $105,455.00 |
DisclosureSEC source: 0001179110-21-009380 · edgar.xml · nonDerivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,846 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2021 Filed Oct 1, 2021 23:32 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 29,450 | $0.00 Strike: $13.10 | $0.00 |
DisclosureSEC source: 0001179110-21-009057 · edgar.xml · derivative · entry 3 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,050 Underlying: Common Stock · 29,450 shares Expires 2024-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on February 6, 2014 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter. Read SEC document |
| October 01, 2021 Filed Oct 1, 2021 23:32 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 29,450 | $39.93 | $1,175,967.95 |
DisclosureSEC source: 0001179110-21-009057 · edgar.xml · nonDerivative · entry 2 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,796 F1 · kind: The option exercise and sale reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $39.528 to $40.50. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range. Read SEC document |
| October 01, 2021 Filed Oct 1, 2021 23:32 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 29,450 | $13.10 | $385,795.00 |
DisclosureSEC source: 0001179110-21-009057 · edgar.xml · nonDerivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,246 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| July 15, 2021 Filed Jul 15, 2021 23:36 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 14,685 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001179110-21-007506 · edgar.xml · derivative · entry 2 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,685 shares Expires 2023-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option was granted on February 4, 2013 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter. Read SEC document |
| July 15, 2021 Filed Jul 15, 2021 23:36 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 14,685 | $6.55 | $96,186.75 |
DisclosureSEC source: 0001179110-21-007506 · edgar.xml · nonDerivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,796 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 21:19 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 40,315 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001179110-21-007391 · edgar.xml · derivative · entry 3 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,685 Underlying: Common Stock · 40,315 shares Expires 2023-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on February 4, 2013 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 21:19 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 40,315 | $45.70 | $1,842,314.87 |
DisclosureSEC source: 0001179110-21-007391 · edgar.xml · nonDerivative · entry 2 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,111 F1 · kind: This disposition was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $45.20 to $46.06. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 21:19 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 40,315 | $6.55 | $264,063.25 |
DisclosureSEC source: 0001179110-21-007391 · edgar.xml · nonDerivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2021 Filed May 4, 2021 00:27 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 11,311 | $0.00 Strike: $11.29 | $0.00 |
DisclosureSEC source: 0001179110-21-004815 · edgar.xml · derivative · entry 2 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,311 shares Expires 2022-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option was granted on February 2, 2012 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter. Read SEC document |
| May 03, 2021 Filed May 4, 2021 00:27 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 11,311 | $11.29 | $127,701.19 |
DisclosureSEC source: 0001179110-21-004815 · edgar.xml · nonDerivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,111 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2021 Filed Apr 1, 2021 23:44 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 28,689 | $0.00 Strike: $11.29 | $0.00 |
DisclosureSEC source: 0001179110-21-003975 · edgar.xml · derivative · entry 4 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,311 Underlying: Common Stock · 28,689 shares Expires 2022-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted on February 2, 2012 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter. Read SEC document |
| April 01, 2021 Filed Apr 1, 2021 23:44 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 18,994 | $42.79 | $812,829.24 |
DisclosureSEC source: 0001179110-21-003975 · edgar.xml · nonDerivative · entry 3 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,800 F1 · kind: This disposition was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $42.41 to $43.09. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range. Read SEC document |
| April 01, 2021 Filed Apr 1, 2021 23:44 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 9,695 | $42.11 | $408,207.98 |
DisclosureSEC source: 0001179110-21-003975 · edgar.xml · nonDerivative · entry 2 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,794 F1 · kind: This disposition was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $41.41 to $42.40. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range. Read SEC document |
| April 01, 2021 Filed Apr 1, 2021 23:44 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 28,689 | $11.29 | $323,898.81 |
DisclosureSEC source: 0001179110-21-003975 · edgar.xml · nonDerivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,489 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 01:06 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 6,530 | $46.26 | $302,060.82 |
DisclosureSEC source: 0001179110-21-002486 · edgar.xml · nonDerivative · entry 2 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,800 F1 · kind: This disposition was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $46.08 to $46.56. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 01:06 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 11,794 | $45.56 | $537,302.80 |
DisclosureSEC source: 0001179110-21-002486 · edgar.xml · nonDerivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,330 F1 · kind: This disposition was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $45.07 to $46.06. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 22, 2021 Filed Feb 22, 2021 23:28 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 8,803 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002057 · edgar.xml · derivative · entry 3 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,803 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F2 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 22, 2021 Filed Feb 22, 2021 23:28 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 4,364 | $48.69 | $212,483.16 |
DisclosureSEC source: 0001179110-21-002057 · edgar.xml · nonDerivative · entry 2 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,124 F1 · shares: The reported disposition of 4,364 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations. Read SEC document |
| February 22, 2021 Filed Feb 22, 2021 23:28 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 8,803 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002057 · edgar.xml · nonDerivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,488 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2021 Filed Feb 17, 2021 22:04 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantRestricted Stock Units · Derivative | 13,544 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-001809 · edgar.xml · derivative · entry 2 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,544 Underlying: Common Stock · 13,544 shares Expires not disclosed F2 · derivative.exercise_date: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter. F2 · derivative.expiration_date: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter. Read SEC document |
| February 15, 2021 Filed Feb 17, 2021 22:04 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantOption to Purchase Common Stock · Derivative | 23,311 | $0.00 Strike: $49.84 | $0.00 |
DisclosureSEC source: 0001179110-21-001809 · edgar.xml · derivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,311 Underlying: Common Stock · 23,311 shares Expires 2031-02-15 F1 · derivative.exercise_date: This option vests one-fourth on such date and then 1/48th monthly thereafter. Read SEC document |
| February 14, 2021 Filed Feb 16, 2021 21:56 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 5,771 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-001690 · edgar.xml · derivative · entry 3 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,771 Underlying: Common Stock · 5,771 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F2 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 14, 2021 Filed Feb 16, 2021 21:56 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 2,272 | $49.84 | $113,236.48 |
DisclosureSEC source: 0001179110-21-001690 · edgar.xml · nonDerivative · entry 2 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,685 F1 · shares: The reported disposition of 2,272 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations. Read SEC document |
| February 14, 2021 Filed Feb 16, 2021 21:56 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 5,771 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-001690 · edgar.xml · nonDerivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,957 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2021 Filed Feb 13, 2021 00:07 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 7,883 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-001652 · edgar.xml · derivative · entry 6 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,766 Underlying: Common Stock · 7,883 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F3 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 12, 2021 Filed Feb 13, 2021 00:07 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 2,725 | $49.84 | $135,814.00 |
DisclosureSEC source: 0001179110-21-001652 · edgar.xml · nonDerivative · entry 4 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,186 F2 · shares: The reported disposition of 2,725 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations. Read SEC document |
| February 12, 2021 Filed Feb 13, 2021 00:07 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 7,883 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-001652 · edgar.xml · nonDerivative · entry 3 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,911 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2021 Filed Feb 13, 2021 00:07 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 8,134 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-001652 · edgar.xml · derivative · entry 5 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,399 Underlying: Common Stock · 8,134 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F3 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 10, 2021 Filed Feb 13, 2021 00:07 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 2,906 | $50.60 | $147,043.60 |
DisclosureSEC source: 0001179110-21-001652 · edgar.xml · nonDerivative · entry 2 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,028 F1 · shares: The reported disposition of 2,906 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations. Read SEC document |
| February 10, 2021 Filed Feb 13, 2021 00:07 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 8,134 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-001652 · edgar.xml · nonDerivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,934 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 21, 2020 Filed Dec 21, 2020 23:01 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 600 | $43.25 | $25,951.20 |
DisclosureSEC source: 0001179110-20-012141 · edgar.xml · nonDerivative · entry 2 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,800 F1 · kind: This disposition was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $43.22 to $43.30. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| December 21, 2020 Filed Dec 21, 2020 23:01 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 11,400 | $42.54 | $484,967.40 |
DisclosureSEC source: 0001179110-20-012141 · edgar.xml · nonDerivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,400 F1 · kind: This disposition was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $42.22 to $43.21. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 20, 2020 Filed Nov 20, 2020 23:25 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 7,889 | $39.04 | $307,955.00 |
DisclosureSEC source: 0001179110-20-011277 · edgar.xml · nonDerivative · entry 2 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,800 F1 · kind: This disposition was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $38.75 to $39.12. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 20, 2020 Filed Nov 20, 2020 23:25 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 4,111 | $38.24 | $157,221.08 |
DisclosureSEC source: 0001179110-20-011277 · edgar.xml · nonDerivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,689 F1 · kind: This disposition was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $37.74 to $38.72. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| October 20, 2020 Filed Oct 20, 2020 20:53 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 12,000 | $30.43 | $365,148.00 |
DisclosureSEC source: 0001179110-20-010606 · edgar.xml · nonDerivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,800 F1 · kind: This disposition was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $29.73 to $30.50. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| September 21, 2020 Filed Sep 21, 2020 23:30 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 12,000 | $26.91 | $322,884.00 |
DisclosureSEC source: 0001179110-20-009905 · edgar.xml · nonDerivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,800 F1 · kind: This disposition was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $26.68 to $27.42. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 20, 2020 Filed Aug 20, 2020 20:21 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 12,000 | $28.30 | $339,564.00 |
DisclosureSEC source: 0001179110-20-009192 · edgar.xml · nonDerivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,800 F1 · kind: This disposition was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $28.05 to $28.56. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| July 20, 2020 Filed Jul 20, 2020 22:33 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 12,000 | $29.01 | $348,072.00 |
DisclosureSEC source: 0001179110-20-008379 · edgar.xml · nonDerivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,800 F1 · kind: This disposition was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $28.61 to $29.29. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range. Read SEC document |
| May 22, 2020 Filed May 22, 2020 22:39 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 18,613 | $0.00 Strike: $7.14 | $0.00 |
DisclosureSEC source: 0001179110-20-006544 · edgar.xml · derivative · entry 2 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,613 shares Expires 2021-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option was granted on February 3, 2011 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter. Read SEC document |
| May 22, 2020 Filed May 22, 2020 22:39 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 18,613 | $7.14 | $132,896.82 |
DisclosureSEC source: 0001179110-20-006544 · edgar.xml · nonDerivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 20, 2020 Filed May 21, 2020 20:11 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 21,387 | $0.00 Strike: $7.14 | $0.00 |
DisclosureSEC source: 0001179110-20-006427 · edgar.xml · derivative · entry 3 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,613 Underlying: Common Stock · 21,387 shares Expires 2021-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on February 3, 2011 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter. Read SEC document |
| May 20, 2020 Filed May 21, 2020 20:11 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 21,387 | $23.80 | $509,074.76 |
DisclosureSEC source: 0001179110-20-006427 · edgar.xml · nonDerivative · entry 2 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,187 F1 · kind: This disposition was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $23.46 to $24.03. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range. Read SEC document |
| May 20, 2020 Filed May 21, 2020 20:11 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 21,387 | $7.14 | $152,703.18 |
DisclosureSEC source: 0001179110-20-006427 · edgar.xml · nonDerivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,574 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2020 Filed Feb 25, 2020 01:04 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 8,803 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002177 · edgar.xml · derivative · entry 3 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,803 Underlying: Common Stock · 8,803 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F2 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 22, 2020 Filed Feb 25, 2020 01:04 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 3,044 | $21.83 | $66,450.52 |
DisclosureSEC source: 0001179110-20-002177 · edgar.xml · nonDerivative · entry 2 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,187 F1 · shares: The reported disposition of 3,044 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations. Read SEC document |
| February 22, 2020 Filed Feb 25, 2020 01:04 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 8,803 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002177 · edgar.xml · nonDerivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,231 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2020 Filed Feb 18, 2020 21:16 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 5,772 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001750 · edgar.xml · derivative · entry 3 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,542 Underlying: Common Stock · 5,772 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F2 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.